NASDAQ:MNTA - Momenta Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$23.40 +0.45 (+1.96 %)
(As of 05/21/2018 03:13 AM ET)
Previous Close$23.40
Today's Range$22.85 - $23.50
52-Week Range$11.85 - $23.50
Volume439,313 shs
Average Volume737,418 shs
Market Capitalization$1.82 billion
P/E Ratio-19.50
Dividend YieldN/A
Beta1.63

About Momenta Pharmaceuticals (NASDAQ:MNTA)

Momenta Pharmaceuticals logoMomenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The company's novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy; M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; and M230, a recombinant trivalent human IgG1 Fc multimer to block tissue damage mediated by immune complexes. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

Receive MNTA News and Ratings via Email

Sign-up to receive the latest news and ratings for MNTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MNTA
CUSIP60877T10
Phone617-491-9700

Debt

Debt-to-Equity RatioN/A
Current Ratio9.80
Quick Ratio9.80

Price-To-Earnings

Trailing P/E Ratio-19.50
Forward P/E Ratio-15.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$138.88 million
Price / Sales13.07
Cash FlowN/A
Price / CashN/A
Book Value$4.31 per share
Price / Book5.43

Profitability

EPS (Most Recent Fiscal Year)($1.20)
Net Income$-88,090,000.00
Net Margins-88.77%
Return on Equity-28.56%
Return on Assets-21.66%

Miscellaneous

Employees279
Outstanding Shares77,590,000

Momenta Pharmaceuticals (NASDAQ:MNTA) Frequently Asked Questions

What is Momenta Pharmaceuticals' stock symbol?

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

How were Momenta Pharmaceuticals' earnings last quarter?

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) posted its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.19. The biotechnology company earned $4.85 million during the quarter, compared to analysts' expectations of $15.63 million. Momenta Pharmaceuticals had a negative return on equity of 28.56% and a negative net margin of 88.77%. The business's revenue for the quarter was down 81.8% compared to the same quarter last year. During the same period last year, the company earned ($0.46) earnings per share. View Momenta Pharmaceuticals' Earnings History.

When is Momenta Pharmaceuticals' next earnings date?

Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Momenta Pharmaceuticals.

What price target have analysts set for MNTA?

7 analysts have issued 12-month target prices for Momenta Pharmaceuticals' shares. Their predictions range from $6.00 to $21.00. On average, they expect Momenta Pharmaceuticals' share price to reach $14.4286 in the next twelve months. View Analyst Ratings for Momenta Pharmaceuticals.

Who are some of Momenta Pharmaceuticals' key competitors?

Who are Momenta Pharmaceuticals' key executives?

Momenta Pharmaceuticals' management team includes the folowing people:
  • Mr. Craig A. Wheeler, Pres, CEO & Exec. Director (Age 58)
  • Dr. Ganesh Venkataraman Kaundinya Ph.D., Co-Founder, COO, Chief Scientific Officer & Sr. VP (Age 51)
  • Mr. Scott M. Storer, Sr. VP, CFO & Principal Accounting Officer
  • Mr. Bruce A. Leicher J.D., Sr. VP, Gen. Counsel and Corp. Sec. (Age 62)
  • Dr. Young T. Kwon Ph.D., Sr. VP of Corp. Devel. & Strategy

Has Momenta Pharmaceuticals been receiving favorable news coverage?

Media headlines about MNTA stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Momenta Pharmaceuticals earned a media sentiment score of 0.09 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 47.03 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Momenta Pharmaceuticals' major shareholders?

Momenta Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.89%), Palo Alto Investors LP (2.36%), Fiera Capital Corp (1.41%), Dimensional Fund Advisors LP (1.32%), Northern Trust Corp (1.19%) and JPMorgan Chase & Co. (0.88%). Company insiders that own Momenta Pharmaceuticals stock include Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, James M Roach, Richard P Shea, Scott M Storer and Young Kwon. View Institutional Ownership Trends for Momenta Pharmaceuticals.

Which major investors are selling Momenta Pharmaceuticals stock?

MNTA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Fiera Capital Corp, Dimensional Fund Advisors LP, Schwab Charles Investment Management Inc., Oppenheimer Asset Management Inc., American International Group Inc. and Wells Fargo & Company MN. Company insiders that have sold Momenta Pharmaceuticals company stock in the last year include Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Scott M Storer and Young Kwon. View Insider Buying and Selling for Momenta Pharmaceuticals.

Which major investors are buying Momenta Pharmaceuticals stock?

MNTA stock was bought by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Eventide Asset Management LLC, Rock Springs Capital Management LP, BlackRock Inc., UBS Group AG, American Century Companies Inc., Mackay Shields LLC and Prudential Financial Inc.. View Insider Buying and Selling for Momenta Pharmaceuticals.

How do I buy shares of Momenta Pharmaceuticals?

Shares of MNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Momenta Pharmaceuticals' stock price today?

One share of MNTA stock can currently be purchased for approximately $23.40.

How big of a company is Momenta Pharmaceuticals?

Momenta Pharmaceuticals has a market capitalization of $1.82 billion and generates $138.88 million in revenue each year. The biotechnology company earns $-88,090,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Momenta Pharmaceuticals employs 279 workers across the globe.

How can I contact Momenta Pharmaceuticals?

Momenta Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-491-9700 or via email at [email protected]


MarketBeat Community Rating for Momenta Pharmaceuticals (MNTA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  378 (Vote Outperform)
Underperform Votes:  350 (Vote Underperform)
Total Votes:  728
MarketBeat's community ratings are surveys of what our community members think about Momenta Pharmaceuticals and other stocks. Vote "Outperform" if you believe MNTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNTA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Momenta Pharmaceuticals (NASDAQ:MNTA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Momenta Pharmaceuticals in the last 12 months. Their average twelve-month price target is $14.4286, suggesting that the stock has a possible downside of 38.34%. The high price target for MNTA is $21.00 and the low price target for MNTA is $6.00. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.001.891.89
Ratings Breakdown: 1 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.4286$14.75$14.7778$14.4444
Price Target Upside: 38.34% downside9.79% downside14.33% downside2.44% upside

Momenta Pharmaceuticals (NASDAQ:MNTA) Consensus Price Target History

Price Target History for Momenta Pharmaceuticals (NASDAQ:MNTA)

Momenta Pharmaceuticals (NASDAQ:MNTA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/22/2018Stifel NicolausUpgradeHold ➝ Buy$18.00 ➝ $21.00HighView Rating Details
11/1/2017CowenSet Price TargetHold$15.00N/AView Rating Details
10/6/2017Robert W. BairdDowngradeBuy ➝ Hold$22.00 ➝ $15.00N/AView Rating Details
10/5/2017JPMorgan ChaseReiterated RatingHold$14.00N/AView Rating Details
10/5/2017Goldman SachsReiterated RatingNeutral$18.00 ➝ $14.00N/AView Rating Details
10/4/2017BarclaysReiterated RatingEqual Weight$17.00 ➝ $16.00HighView Rating Details
8/3/2017Maxim GroupSet Price TargetSell$6.00LowView Rating Details
5/3/2017AegisReiterated RatingHold$17.00LowView Rating Details
2/21/2017Leerink SwannDowngradeOutperform ➝ Market Perform$18.00 ➝ $18.00N/AView Rating Details
8/5/2016Brean CapitalSet Price TargetBuy$19.00N/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Momenta Pharmaceuticals (NASDAQ:MNTA) Earnings History and Estimates Chart

Earnings by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Momenta Pharmaceuticals (NASDAQ:MNTA) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.56 EPS
Next Year EPS Consensus Estimate: $-0.74 EPS

Momenta Pharmaceuticals (NASDAQ MNTA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2018($0.32)N/AView Earnings Details
5/8/2018Q1 2018($0.44)($0.63)$15.63 million$4.85 millionViewListenView Earnings Details
2/21/2018Q4 2017$0.06$0.18$66.59 million$64.60 millionViewListenView Earnings Details
11/1/2017Q3 2017($0.47)($0.44)$29.58 million$24.09 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.50)($0.50)$24.64 million$23.57 millionViewListenView Earnings Details
5/2/2017Q1 2017($1.09)($0.46)$21.29 million$26.61 millionViewListenView Earnings Details
2/21/2017Q416($0.24)$0.60$29.56 million$34.20 millionViewListenView Earnings Details
11/2/2016Q316($0.29)($0.26)$25.68 million$299.14 millionViewN/AView Earnings Details
8/4/2016Q216($0.34)($0.31)$23.55 million$26.40 millionViewN/AView Earnings Details
5/3/2016Q116($0.32)($0.35)$28.12 million$19.90 millionViewN/AView Earnings Details
2/18/2016Q415($0.04)($0.43)$30.42 million$22.40 millionViewListenView Earnings Details
11/4/2015Q315($0.19)($0.44)$31.76 million$13.80 millionViewListenView Earnings Details
8/4/2015Q215($0.39)($0.04)$23.59 million$44.90 millionViewListenView Earnings Details
5/1/2015Q115($0.48)($0.40)$11.70 million$8.60 millionViewN/AView Earnings Details
2/17/2015Q414($0.16)($0.31)$23.80 million$21.18 millionViewListenView Earnings Details
11/5/2014Q314($0.43)($0.56)$13.00 million$9.34 millionViewListenView Earnings Details
7/31/2014Q214($0.49)($0.51)$11.22 million$11.00 millionViewListenView Earnings Details
5/6/2014Q1($0.55)($0.53)$8.41 million$10.79 millionViewListenView Earnings Details
2/10/2014Q4($0.45)($0.59)$8.50 million$12.80 millionViewListenView Earnings Details
11/5/2013Q313($0.48)($0.50)$8.60 million$10.80 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.45)($0.57)$8.85 million$4.40 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.44)($0.48)$10.28 million$7.60 millionViewN/AView Earnings Details
2/15/2013Q4 2012($0.41)($0.35)$10.41 million$12.70 millionViewN/AView Earnings Details
11/7/2012Q312($0.27)($0.51)$16.48 million$5.10 millionViewN/AView Earnings Details
8/2/2012($0.17)($0.20)ViewN/AView Earnings Details
5/3/2012$0.02($0.10)ViewN/AView Earnings Details
2/9/2012$0.13($0.02)ViewN/AView Earnings Details
11/7/2011$1.28$1.18ViewN/AView Earnings Details
8/4/2011$1.21$1.26ViewN/AView Earnings Details
5/5/2011$0.95$1.13ViewN/AView Earnings Details
2/10/2011$0.81$0.77ViewN/AView Earnings Details
11/1/2010Q3 2010$0.42$0.70ViewN/AView Earnings Details
8/2/2010Q2 2010($0.35)($0.34)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.34)($0.37)ViewN/AView Earnings Details
2/11/2010Q4 2009($0.35)($0.34)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.40)($0.38)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.44)($0.43)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.47)($0.46)ViewN/AView Earnings Details
2/12/2009Q4 2008($0.44)($0.50)ViewN/AView Earnings Details
11/3/2008Q3 2008($0.43)($0.45)ViewN/AView Earnings Details
7/24/2008Q2 2008($0.43)($0.42)ViewN/AView Earnings Details
5/7/2008Q1 2008($0.56)($0.37)ViewN/AView Earnings Details
2/14/2008Q4 2007($0.60)($0.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Momenta Pharmaceuticals (NASDAQ:MNTA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Momenta Pharmaceuticals (NASDAQ MNTA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 96.43%
Insider Trading History for Momenta Pharmaceuticals (NASDAQ:MNTA)
Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Momenta Pharmaceuticals (NASDAQ MNTA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/10/2018Craig A WheelerCEOSell1,772$21.86$38,735.92198,987View SEC Filing  
5/10/2018Young KwonSVPSell352$21.95$7,726.40141,975View SEC Filing  
5/8/2018Bruce LeicherSVPSell471$18.08$8,515.68172,188View SEC Filing  
5/8/2018Craig A WheelerCEOSell2,601$20.21$52,566.21203,360View SEC Filing  
5/8/2018Ganesh Venkataraman KaundinyaCOOSell493$18.09$8,918.37496,709View SEC Filing  
5/2/2018Craig A WheelerCEOSell80,770$20.86$1,684,862.20View SEC Filing  
4/26/2018Elizabeth StonerDirectorSell3,857$20.00$77,140.0021,684View SEC Filing  
4/19/2018Craig A WheelerCEOSell5,896$21.00$123,816.00198,479View SEC Filing  
4/19/2018Young KwonSVPSell15,089$20.90$315,360.10147,411View SEC Filing  
4/12/2018Elizabeth StonerDirectorSell7,714$20.00$154,280.0029,378View SEC Filing  
4/10/2018Craig A. WheelerCEOSell43,334$19.00$823,346.00View SEC Filing  
4/10/2018Elizabeth StonerDirectorSell3,399$19.00$64,581.0022,777View SEC Filing  
3/21/2018Elizabeth StonerDirectorSell3,399$19.00$64,581.0021,176View SEC Filing  
2/21/2018Bruce LeicherSVPSell728$15.90$11,575.20171,194View SEC Filing  
2/21/2018Craig A WheelerCEOSell3,938$16.46$64,819.48239,869View SEC Filing  
2/21/2018Ganesh Venkataraman KaundinyaCOOSell745$15.90$11,845.50495,686View SEC Filing  
2/14/2018Bruce LeicherSVPSell4,948$15.22$75,308.56176,210View SEC Filing  
2/14/2018Craig A WheelerCEOSell18,648$16.14$300,978.72258,713View SEC Filing  
2/14/2018Ganesh Venkataraman KaundinyaCOOSell4,986$15.23$75,936.78501,031View SEC Filing  
2/14/2018Scott M. StorerCFOSell3,972$15.16$60,215.52View SEC Filing  
2/12/2018Bruce LeicherSVPSell309$16.20$5,005.80176,210View SEC Filing  
2/12/2018Craig A WheelerCEOSell1,773$16.18$28,687.14258,713View SEC Filing  
2/12/2018Ganesh Venkataraman KaundinyaCOOSell341$16.20$5,524.20501,031View SEC Filing  
2/8/2018Bruce LeicherSVPSell1,861$16.00$29,776.00View SEC Filing  
2/8/2018Craig A WheelerCEOSell10,406$15.89$165,351.34275,526View SEC Filing  
2/8/2018Ganesh Venkataraman KaundinyaCOOSell1,917$16.00$30,672.00492,845View SEC Filing  
1/30/2018Elizabeth StonerDirectorSell16,264$18.00$292,752.0032,440View SEC Filing  
1/2/2018Craig A WheelerCEOSell35,666$14.11$503,247.26View SEC Filing  
12/13/2017Elizabeth StonerDirectorSell5,500$13.10$72,050.0013,240View SEC Filing  
11/21/2017Bruce LeicherSVPSell803$13.15$10,559.45172,906View SEC Filing  
11/21/2017Craig A. WheelerCEOSell4,116$13.35$54,948.60View SEC Filing  
11/21/2017Ganesh Venkataraman KaundinyaCOOSell821$13.15$10,796.15487,633View SEC Filing  
11/10/2017Bruce LeicherSVPSell355$13.07$4,639.85173,322View SEC Filing  
11/10/2017Craig A WheelerCEOSell1,852$13.25$24,539.00258,602View SEC Filing  
11/10/2017Ganesh Venkataraman KaundinyaCOOSell392$13.12$5,143.04488,029View SEC Filing  
9/28/2017Craig A WheelerPresidentSell35,667$19.03$678,743.01286,121View SEC Filing  
9/1/2017Craig A. WheelerPresidentSell20,367$17.00$346,239.00View SEC Filing  
8/21/2017Bruce LeicherSVPSell802$15.20$12,190.40174,064View SEC Filing  
8/21/2017Craig A WheelerPresidentSell4,116$15.07$62,028.12269,231View SEC Filing  
8/21/2017Ganesh Venkataraman KaundinyaVPSell821$15.20$12,479.20488,846View SEC Filing  
8/10/2017Bruce LeicherSVPSell350$16.60$5,810.00View SEC Filing  
8/10/2017Craig A. WheelerPresidentSell16,953$16.94$287,183.82View SEC Filing  
8/10/2017Ganesh Venkataraman KaundinyaVPSell387$16.60$6,424.20489,242View SEC Filing  
8/2/2017Craig A WheelerPresidentSell200$17.00$3,400.00279,961View SEC Filing  
5/22/2017Bruce LeicherSVPSell859$14.80$12,713.20View SEC Filing  
5/19/2017Craig A WheelerPresidentSell4,116$15.83$65,156.28281,919View SEC Filing  
5/19/2017Ganesh Venkataraman KaundinyaVPSell821$15.90$13,053.90View SEC Filing  
5/10/2017Bruce LeicherSVPSell347$16.00$5,552.00175,205View SEC Filing  
5/10/2017Craig A. WheelerPresidentSell1,852$15.77$29,206.04View SEC Filing  
5/10/2017Ganesh Venkataraman KaundinyaVPSell384$16.00$6,144.00490,453View SEC Filing  
12/15/2016Richard P SheaCFOSell9,799$15.00$146,985.00121,972View SEC Filing  
12/9/2016Richard P SheaCFOSell1,451$15.00$21,765.00129,705View SEC Filing  
11/22/2016Bruce LeicherSVPSell1,030$13.66$14,069.80View SEC Filing  
11/22/2016Craig A. WheelerPresidentSell5,880$13.68$80,438.40View SEC Filing  
11/22/2016James M RoachVPSell1,091$13.67$14,913.97156,056View SEC Filing  
11/22/2016Richard P SheaCFOSell971$13.67$13,273.57131,731View SEC Filing  
8/22/2016Bruce LeicherSVPSell1,030$12.05$12,411.50183,566View SEC Filing  
8/22/2016Craig A. WheelerPresidentSell5,880$12.02$70,677.60View SEC Filing  
8/22/2016James M RoachVPSell1,091$12.05$13,146.55157,147View SEC Filing  
8/22/2016Richard P SheaCFOSell972$12.05$11,712.60132,703View SEC Filing  
5/20/2016Bruce LeicherSVPSell1,000$10.40$10,400.00184,576View SEC Filing  
5/20/2016Craig A WheelerPresidentSell5,880$10.18$59,858.40349,521View SEC Filing  
5/20/2016Ganesh Venkataraman KaundinyaVPSell1,050$10.18$10,689.00456,765View SEC Filing  
5/20/2016Richard P SheaCFOSell973$10.18$9,905.14133,675View SEC Filing  
5/19/2016John E BishopVPSell784$10.20$7,996.80157,640View SEC Filing  
4/19/2016John E BishopVPSell2,843$9.57$27,207.51160,880View SEC Filing  
2/23/2016John E BishopVPSell329$9.70$3,191.30107,188View SEC Filing  
2/22/2016Bruce LeicherSVPSell227$9.65$2,190.55131,188View SEC Filing  
2/22/2016Craig A WheelerPresidentSell1,688$9.95$16,795.60244,342View SEC Filing  
2/22/2016John E BishopVPSell2,848$9.66$27,511.68109,859View SEC Filing  
2/19/2016Bruce LeicherSVPSell2,000$9.64$19,280.00132,991View SEC Filing  
2/19/2016Craig A WheelerPresidentSell9,844$9.37$92,238.28253,905View SEC Filing  
2/19/2016John E. BishopVPSell357$10.28$3,669.96110,263View SEC Filing  
2/19/2016Richard P SheaCFOSell1,823$9.64$17,573.72141,924View SEC Filing  
2/18/2016Bruce LeicherSVPSell337$10.49$3,535.13133,415View SEC Filing  
2/18/2016James M RoachVPSell272$10.49$2,853.28107,269View SEC Filing  
2/18/2016Richard P SheaCFOSell183$10.49$1,919.67142,328View SEC Filing  
2/17/2016Craig A WheelerPresidentSell1,688$11.30$19,074.40255,874View SEC Filing  
12/11/2015Michael FrankenInsiderSell520$15.84$8,236.8037,968View SEC Filing  
11/20/2015Craig A WheelerPresidentSell1,766$17.86$31,540.76200,844View SEC Filing  
11/19/2015Craig A WheelerPresidentSell2,061$18.05$37,201.05202,610View SEC Filing  
11/17/2015Craig A WheelerPresidentSell1,766$17.70$31,258.20204,671View SEC Filing  
11/5/2015Craig A. WheelerPresidentSell51,667$18.00$930,006.00206,437View SEC Filing  
8/20/2015Craig A WheelerPresidentSell1,766$22.28$39,346.48212,719View SEC Filing  
8/19/2015Craig A WheelerPresidentSell2,061$22.02$45,383.22214,485View SEC Filing  
8/19/2015James M. RoachVPSell7,011$22.09$154,872.9992,079View SEC Filing  
8/18/2015James M RoachVPSell6,812$21.80$148,501.60View SEC Filing  
8/17/2015Craig A WheelerPresidentSell1,766$21.77$38,445.82216,546View SEC Filing  
7/15/2015Elizabeth StonerDirectorSell4,570$22.35$102,139.50View SEC Filing  
6/19/2015John E BishopVPSell21,274$25.50$542,487.00View SEC Filing  
6/18/2015Bruce LeicherSVPSell20,000$23.00$460,000.00View SEC Filing  
6/18/2015Craig A WheelerPresidentSell155,000$24.20$3,751,000.00View SEC Filing  
6/18/2015John E BishopVPSell36,313$23.58$856,260.54View SEC Filing  
6/4/2015Craig A WheelerPresidentSell103,333$22.00$2,273,326.00View SEC Filing  
6/1/2015Bruce LeicherSVPSell40,000$21.00$840,000.00View SEC Filing  
6/1/2015James M RoachVPSell25,000$21.70$542,500.00View SEC Filing  
5/20/2015Craig A WheelerPresidentSell1,766$19.68$34,754.88View SEC Filing  
5/19/2015Craig A WheelerPresidentSell2,061$19.67$40,539.87View SEC Filing  
4/23/2015Craig A WheelerPresidentSell51,667$20.00$1,033,340.00View SEC Filing  
4/23/2015Ganesh Venkataraman KaundinyaVPSell34,000$19.95$678,300.00View SEC Filing  
4/20/2015Craig A WheelerPresidentSell6,269$18.75$117,543.75View SEC Filing  
4/17/2015Bruce LeicherSVPSell52,910$19.52$1,032,803.20View SEC Filing  
4/16/2015James M RoachVPSell50,000$18.70$935,000.00View SEC Filing  
3/16/2015Richard P SheaCFOSell23,093$15.10$348,704.30View SEC Filing  
3/5/2015Richard P SheaCFOSell23,364$14.90$348,123.60View SEC Filing  
2/24/2015Craig A WheelerPresidentSell2,110$13.52$28,527.20View SEC Filing  
2/20/2015Bruce LeicherSVPSell1,891$12.97$24,526.27View SEC Filing  
2/20/2015Craig A WheelerPresidentSell9,563$13.49$129,004.87View SEC Filing  
2/20/2015John E BishopVPSell1,768$12.97$22,930.96View SEC Filing  
2/20/2015Richard P SheaCFOSell1,812$12.97$23,501.64View SEC Filing  
2/18/2015Craig A WheelerPresidentSell1,688$11.91$20,104.08View SEC Filing  
12/15/2014Bennett M ShapiroDirectorSell5,800$12.19$70,702.00View SEC Filing  
12/11/2014Michael FrankenInsiderSell2,047$12.29$25,157.63View SEC Filing  
12/1/2014Bennett M ShapiroDirectorSell9,903$12.00$118,836.00View SEC Filing  
11/28/2014Bennett M ShapiroDirectorSell1,897$12.00$22,764.00View SEC Filing  
11/25/2014Craig A WheelerPresidentSell2,210$11.59$25,613.90View SEC Filing  
11/20/2014Craig A WheelerPresidentSell1,768$11.10$19,624.80View SEC Filing  
11/17/2014Craig A WheelerPresidentSell1,768$10.58$18,705.44View SEC Filing  
10/3/2014Bennett M ShapiroDirectorSell3,723$12.00$44,676.00View SEC Filing  
9/12/2014Peter Barton HuttDirectorSell3,640$11.42$41,568.80View SEC Filing  
8/25/2014Craig A WheelerPresidentSell2,209$11.45$25,293.05View SEC Filing  
8/20/2014Craig A WheelerPresidentSell1,768$11.54$20,402.72View SEC Filing  
8/15/2014Bennett M ShapiroDirectorSell3,722$12.00$44,664.00View SEC Filing  
8/15/2014Craig A WheelerPresidentSell1,768$11.75$20,774.00View SEC Filing  
8/13/2014Bennett M ShapiroDirectorSell3,721$12.00$44,652.00View SEC Filing  
5/23/2014Craig A WheelerPresidentSell2,110$12.06$25,446.60View SEC Filing  
5/20/2014Craig WheelerPresidentSell1,688$12.08$20,391.04376,164View SEC Filing  
5/15/2014Craig WheelerPresidentSell1,687$11.09$18,708.83377,852View SEC Filing  
2/25/2014Craig WheelerPresidentSell2,109$17.47$36,844.23379,539View SEC Filing  
2/24/2014John BishopVPSell1,038$17.67$18,341.46111,621View SEC Filing  
2/19/2014Craig WheelerPresidentSell3,797$17.90$67,966.30388,398View SEC Filing  
2/12/2014Ganesh Venkataraman KaundinyaVPSell33,000$17.96$592,680.00346,129View SEC Filing  
1/9/2014John BishopVPSell27,159$19.50$529,600.5093,780View SEC Filing  
11/25/2013Bruce LeicherSVPSell13,492$18.00$242,856.00108,975View SEC Filing  
11/25/2013Craig WheelerPresidentSell2,215$17.77$39,360.55322,195View SEC Filing  
11/25/2013Ganesh Venkataraman KaundinyaVPSell33,211$18.02$598,462.22391,129View SEC Filing  
11/19/2013Craig WheelerPresidentSell2,215$17.17$38,031.55324,410View SEC Filing  
11/15/2013Craig WheelerPresidentSell1,772$16.88$29,911.36326,625View SEC Filing  
10/11/2013John BishopVPSell5,247$15.46$81,118.6294,618View SEC Filing  
8/23/2013Craig WheelerPresidentSell2,109$14.90$31,424.10328,397View SEC Filing  
8/20/2013Craig WheelerPresidentSell2,109$14.47$30,517.23330,506View SEC Filing  
8/15/2013Craig WheelerPresidentSell1,688$15.43$26,045.84332,615View SEC Filing  
7/26/2013Richard P SheaCFOSell30,000$16.61$498,300.00View SEC Filing  
6/27/2013Richard P SheaCFOSell10,522$14.61$153,726.42View SEC Filing  
6/19/2013Richard P SheaCFOSell21,550$14.61$314,845.50View SEC Filing  
5/23/2013Craig A WheelerPresidentSell2,109$13.03$27,480.27View SEC Filing  
5/21/2013Craig A WheelerPresidentSell2,109$12.83$27,058.47View SEC Filing  
5/15/2013Craig A WheelerPresidentSell1,687$13.33$22,487.71View SEC Filing  
3/5/2013Elizabeth StonerDirectorSell2,040$14.00$28,560.00View SEC Filing  
2/15/2013Bruce LeicherSVPSell1,040$12.26$12,750.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Momenta Pharmaceuticals (NASDAQ MNTA) News Headlines

Source:
DateHeadline
On The Radar: Momenta Is Primed For Biosimilar MomentumOn The Radar: Momenta Is Primed For Biosimilar Momentum
seekingalpha.com - May 18 at 10:23 AM
Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on AutoimmunityMomenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity
finance.yahoo.com - May 17 at 4:47 PM
Teva Stock Up 5% as Buffetts Berkshire Raises Stake in Q1Teva Stock Up 5% as Buffett's Berkshire Raises Stake in Q1
www.zacks.com - May 16 at 9:44 AM
Momenta Pharmaceuticals Contemplates Its FutureMomenta Pharmaceuticals Contemplates Its Future
www.fool.com - May 15 at 2:42 PM
Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig A. Wheeler Sells 1,772 SharesMomenta Pharmaceuticals, Inc. (MNTA) CEO Craig A. Wheeler Sells 1,772 Shares
www.americanbankingnews.com - May 14 at 8:18 PM
Teva’s Copaxone Maintains Market Share amid Intense CompetitionTeva’s Copaxone Maintains Market Share amid Intense Competition
finance.yahoo.com - May 14 at 4:29 PM
Momenta Pharmaceuticals, Inc. (MNTA) Given Average Rating of "Hold" by BrokeragesMomenta Pharmaceuticals, Inc. (MNTA) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 13 at 10:11 AM
 Brokerages Expect Momenta Pharmaceuticals, Inc. (MNTA) Will Post Quarterly Sales of $24.63 Million Brokerages Expect Momenta Pharmaceuticals, Inc. (MNTA) Will Post Quarterly Sales of $24.63 Million
www.americanbankingnews.com - May 12 at 3:50 AM
Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig A. Wheeler Sells 2,601 SharesMomenta Pharmaceuticals, Inc. (MNTA) CEO Craig A. Wheeler Sells 2,601 Shares
www.americanbankingnews.com - May 10 at 8:33 PM
Momenta Pharmaceuticals (MNTA) Downgraded to "D" at TheStreetMomenta Pharmaceuticals (MNTA) Downgraded to "D" at TheStreet
www.americanbankingnews.com - May 10 at 6:38 PM
Momenta Pharmaceuticals to Webcast Presentation at the Bank of America Merrill Lynch Health Care Conference 2018Momenta Pharmaceuticals to Webcast Presentation at the Bank of America Merrill Lynch Health Care Conference 2018
www.nasdaq.com - May 10 at 9:42 AM
Edited Transcript of MNTA earnings conference call or presentation 8-May-18 12:00pm GMTEdited Transcript of MNTA earnings conference call or presentation 8-May-18 12:00pm GMT
finance.yahoo.com - May 10 at 9:42 AM
Zacks: Brokerages Anticipate Momenta Pharmaceuticals, Inc. (MNTA) to Post -$0.25 EPSZacks: Brokerages Anticipate Momenta Pharmaceuticals, Inc. (MNTA) to Post -$0.25 EPS
www.americanbankingnews.com - May 10 at 9:22 AM
Momenta Pharmaceuticals (MNTA) Q1 2018 Earnings Conference Call TranscriptMomenta Pharmaceuticals (MNTA) Q1 2018 Earnings Conference Call Transcript
www.fool.com - May 9 at 12:58 PM
Momenta (MNTA) Incurs Wider Y/Y Loss, Glatopa Sales DeclineMomenta (MNTA) Incurs Wider Y/Y Loss, Glatopa Sales Decline
www.zacks.com - May 9 at 9:31 AM
Momenta Pharmaceuticals (MNTA) CEO Craig Wheeler on Q1 2018 Results - Earnings Call TranscriptMomenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 4:26 PM
Momenta Pharmaceuticals (MNTA) Posts  Earnings Results, Misses Estimates By $0.15 EPSMomenta Pharmaceuticals (MNTA) Posts Earnings Results, Misses Estimates By $0.15 EPS
www.americanbankingnews.com - May 8 at 9:34 AM
Momenta: 1Q Earnings SnapshotMomenta: 1Q Earnings Snapshot
www.cnbc.com - May 8 at 9:24 AM
Momenta Pharmaceuticals misses by $0.15, misses on revenueMomenta Pharmaceuticals misses by $0.15, misses on revenue
seekingalpha.com - May 8 at 9:24 AM
Insider Selling: Momenta Pharmaceuticals, Inc. (MNTA) CEO Sells 80,770 Shares of StockInsider Selling: Momenta Pharmaceuticals, Inc. (MNTA) CEO Sells 80,770 Shares of Stock
www.americanbankingnews.com - May 3 at 7:33 PM
Momenta Pharmaceuticals (MNTA) Downgraded by ValuEngineMomenta Pharmaceuticals (MNTA) Downgraded by ValuEngine
www.americanbankingnews.com - May 2 at 11:38 PM
Boston biotech entrepreneur Christoph Westphal launches new startupBoston biotech entrepreneur Christoph Westphal launches new startup
finance.yahoo.com - May 2 at 4:30 PM
Momenta Pharmaceuticals (MNTA) Lifted to Strong-Buy at BidaskClubMomenta Pharmaceuticals (MNTA) Lifted to Strong-Buy at BidaskClub
www.americanbankingnews.com - May 2 at 1:04 PM
Insider Selling: Momenta Pharmaceuticals, Inc. (MNTA) Director Sells 3,857 Shares of StockInsider Selling: Momenta Pharmaceuticals, Inc. (MNTA) Director Sells 3,857 Shares of Stock
www.americanbankingnews.com - April 27 at 7:26 PM
Momenta Pharmaceuticals, Inc. (MNTA) CEO Sells $123,816.00 in StockMomenta Pharmaceuticals, Inc. (MNTA) CEO Sells $123,816.00 in Stock
www.americanbankingnews.com - April 23 at 7:28 PM
Momenta Pharmaceuticals, Inc. (MNTA) SVP Young Kwon Sells 15,089 SharesMomenta Pharmaceuticals, Inc. (MNTA) SVP Young Kwon Sells 15,089 Shares
www.americanbankingnews.com - April 23 at 7:10 PM
Momenta Pharmaceuticals (MNTA) to Release Earnings on MondayMomenta Pharmaceuticals (MNTA) to Release Earnings on Monday
www.americanbankingnews.com - April 23 at 6:36 AM
Momenta Pharmaceuticals, Inc. (MNTA) Receives Average Recommendation of "Hold" from AnalystsMomenta Pharmaceuticals, Inc. (MNTA) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 18 at 9:40 AM
Momenta Pharmaceuticals (MNTA) Rating Reiterated by Stifel NicolausMomenta Pharmaceuticals (MNTA) Rating Reiterated by Stifel Nicolaus
www.americanbankingnews.com - April 13 at 9:27 PM
Maxim Group Reiterates $6.00 Price Target for Momenta Pharmaceuticals (MNTA)Maxim Group Reiterates $6.00 Price Target for Momenta Pharmaceuticals (MNTA)
www.americanbankingnews.com - April 13 at 7:15 PM
Elizabeth Stoner Sells 7,714 Shares of Momenta Pharmaceuticals, Inc. (MNTA) StockElizabeth Stoner Sells 7,714 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock
www.americanbankingnews.com - April 13 at 7:11 PM
Momenta Pharmaceuticals, Inc. (MNTA) Director Sells $64,581.00 in StockMomenta Pharmaceuticals, Inc. (MNTA) Director Sells $64,581.00 in Stock
www.americanbankingnews.com - April 12 at 7:35 PM
Elizabeth Stoner Sells 3,399 Shares of Momenta Pharmaceuticals, Inc. (MNTA) StockElizabeth Stoner Sells 3,399 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock
www.americanbankingnews.com - April 12 at 7:35 PM
Momenta Pharmaceuticals, Inc. (MNTA) CEO Sells $823,346.00 in StockMomenta Pharmaceuticals, Inc. (MNTA) CEO Sells $823,346.00 in Stock
www.americanbankingnews.com - April 12 at 7:17 PM
Momenta Pharmaceuticals (MNTA) Hold Rating Reiterated at Stifel NicolausMomenta Pharmaceuticals' (MNTA) Hold Rating Reiterated at Stifel Nicolaus
www.americanbankingnews.com - April 8 at 12:40 AM
Momenta Pharmaceuticals (MNTA) Stock Rating Upgraded by BidaskClubMomenta Pharmaceuticals (MNTA) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 5 at 12:31 AM
Momenta Pharmaceuticals (MNTA) Stock Rating Upgraded by ValuEngineMomenta Pharmaceuticals (MNTA) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 3 at 11:31 PM
Momenta Pharmaceuticals (MNTA) Given a $15.00 Price Target at CowenMomenta Pharmaceuticals (MNTA) Given a $15.00 Price Target at Cowen
www.americanbankingnews.com - April 2 at 4:16 PM
How Did Sandoz Perform in 4Q17 and Fiscal 2017?How Did Sandoz Perform in 4Q17 and Fiscal 2017?
finance.yahoo.com - April 2 at 9:57 AM
Momenta Pharmaceuticals (MNTA) Upgraded by BidaskClub to BuyMomenta Pharmaceuticals (MNTA) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - March 30 at 2:19 PM
Analyzing Momenta Pharmaceuticals (MNTA) and Gemphire Therapeutics (GEMP)Analyzing Momenta Pharmaceuticals (MNTA) and Gemphire Therapeutics (GEMP)
www.americanbankingnews.com - March 29 at 11:06 PM
Momenta Pharmaceuticals (MNTA) Rating Lowered to Hold at BidaskClubMomenta Pharmaceuticals (MNTA) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - March 27 at 4:34 PM
Momenta Pharmaceuticals (MNTA) Downgraded by BidaskClubMomenta Pharmaceuticals (MNTA) Downgraded by BidaskClub
www.americanbankingnews.com - March 27 at 3:28 PM
Momenta Pharmaceuticals, Inc. (MNTA) Receives Average Rating of "Hold" from BrokeragesMomenta Pharmaceuticals, Inc. (MNTA) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 24 at 9:56 AM
Sectoral Asset Management Inc Grows Stake in Momenta Pharmaceuticals, Inc. (MNTA)Sectoral Asset Management Inc Grows Stake in Momenta Pharmaceuticals, Inc. (MNTA)
www.americanbankingnews.com - March 5 at 3:35 PM
Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor ConferencesMomenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
finance.yahoo.com - March 5 at 9:44 AM
Reviewing Global Blood Therapeutics (GBT) and Momenta Pharmaceuticals (MNTA)Reviewing Global Blood Therapeutics (GBT) and Momenta Pharmaceuticals (MNTA)
www.americanbankingnews.com - March 5 at 3:08 AM
Momenta Pharmaceuticals, Inc. (MNTA) Given Average Recommendation of "Hold" by AnalystsMomenta Pharmaceuticals, Inc. (MNTA) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 27 at 12:32 PM
Momenta Pharmaceuticals Inc (MNTA) Files 10-K for the Fiscal Year Ended on December 31, 2017Momenta Pharmaceuticals Inc (MNTA) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 26 at 4:57 PM
Momenta Pharmaceuticals (MNTA) Stock Rating Lowered by BidaskClubMomenta Pharmaceuticals (MNTA) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - February 25 at 4:54 PM

SEC Filings

Momenta Pharmaceuticals (NASDAQ:MNTA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Momenta Pharmaceuticals (NASDAQ:MNTA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Momenta Pharmaceuticals (NASDAQ MNTA) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.